ASCO 2022: Advancing Therapies in Metastatic Breast Cancer

Tarah J. Ballinger, MD


May 26, 2022

Tarah J. Ballinger, MD, discusses several trials in metastatic breast cancer (mBC) being presented at the upcoming 2022 American Society of Clinical Oncology Annual Meeting. The first study data that Dr Ballinger is excited to learn about are from DESTINY-Breast04, which evaluated patients with HER2-low tumor expression treated with trastuzumab deruxtecan, an antibody-drug conjugate (ADC) that has led to practice-changing results in patients with HER2-positive mBC. Next, Dr Ballinger looks forward to positive results from the TROPiCS-02 study on the efficacy of another ADC, sacituzumab govitecan, in patients with metastatic hormone-refractory breast cancer.

Dr Ballinger also awaits the results from the MAINTAIN trial which seeks to answer the question about whether to continue CDK4/6 inhibitors in patients with metastatic HR-positive breast cancer after progression of disease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.